Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
CAMBRIDGE, Mass., March 16, 2016 -- Jounce Therapeutics, Inc., a company focused on the discovery and development of novel cancer immunotherapies coupled to patient enrichment strategies, today announced that advances within the company’s immuno-oncology pipeline will be presented during two poster presentations on Sunday, April 17, 2016 at the American Association of Cancer Research (AACR) Annual Meeting 2016. The meeting is being held April 16-20, 2016 at the Ernest N. Morial Convention Center in New Orleans.
The abstracts are now available on the AACR website. Jounce’s presentation details are as follows:
Title: Preclinical evaluation of JTX-2011, an anti-ICOS agonist antibody
Abstract Code: 573
Poster Number: 4
Poster Session: PO.IM02.09 Therapeutic Antibodies
Date: Sunday, April 17, 2016
Session Time: 1:00-5:00p.m. ET
Location: Section 27
Title: Discovery of a novel TIM3 binding partner and a key role for TIM3 on macrophages: identification of specific antibodies capable of converting immune-suppressive macrophages to immune-enhancing
Abstract Number: 586
Poster Number: 17
Poster Session: PO.IM02.09 Therapeutic Antibodies
Date: Sunday, April 17, 2016
Session Time: 1:00-5:00p.m. ET
Location: Section 27
About Jounce Therapeutics
Jounce Therapeutics is an immuno-oncology company dedicated to transforming the treatment of cancer. The company is discovering and developing novel cancer immunotherapies designed to harness the immune system to attack tumors and provide long-lasting benefits to patients. Jounce integrates translational science insights, including identification of related biomarkers, designed to match the right immunotherapy to the right patients. The company is advancing programs that leverage contributions from its world-class founders, as well as knowledge acquired from Jounce’s translational science platform, to create a sustainable “discovery to human proof-of-concept” product engine with the potential to drive significantly more durable responses to treatment. Founded by world leaders in tumor immunology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013 with funding from leading life sciences investor, Third Rock Ventures. For more information, please visit www.jouncetx.com.
Media Contact: Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected]
